Human metapneumovirus (hMPV) of the family *Paramyxoviridae* and subfamily *Pneumoviridae* was first discovered in The Netherlands from infants and children suffering from acute respiratory tract disease ([@bib43]). Since then considerable progress has been made in identification and characterization ([@bib7], [@bib26], [@bib12], [@bib28], [@bib36], [@bib19], [@bib24], [@bib16], [@bib15], [@bib40], [@bib41]) as well as in understanding its genetic diversity ([@bib2], [@bib1], [@bib3], [@bib21], [@bib31], [@bib5], [@bib25], [@bib14], [@bib4]). To date this virus has been identified in many countries from different age groups and reported to cause upper respiratory tract infections, flu-like infections, and has also been associated with lower respiratory tract infections ([@bib43], [@bib37], [@bib3], [@bib2], [@bib1], [@bib21], [@bib31], [@bib5], [@bib25], [@bib13], [@bib34], [@bib14], [@bib22], [@bib16], [@bib15]), a pattern similar to that reported for human respiratory syncytial virus (HRSV). Although comparative genome mapping analyses suggested that this virus has structural and functional similarities with HRSV ([@bib22]), recent studies reported that the attachment (G) glycoprotein of these paramimyxoviruses exhibit extensive nucleotide and amino acid variation, with most differences located in the extracellular domain ([@bib31], [@bib22]). Therefore, G-protein has been widely used to infer evolutionary relationships among the isolates from different geographic regions (e.g., [@bib31], [@bib21]). Although phylogenetic analyses of hMPVs from the complete nucleotide coding sequences revealed the existence of two major lineages of hMPVs ([@bib21]), recent analyses based on G-protein phylogeny revealed the existence of two minor sub-groups within each major lineage ([@bib31]). Despite the knowledge of identification and characterization of hMPVs, the possible mechanism by which hMPV G-proteins have evolved is poorly understood.

Earlier studies on the molecular evolution of HRSV G-protein reported that certain amino acid sites that correspond to sites of *O*-glycosylation, or amino acid sites that were previously described as monoclonal antibody-induced in vitro escape mutants, are under positive selection and thus showed strong association between these positively selected sites and the mapped neutralizing epitopes ([@bib53]). Recently, [@bib51] also reported that certain amino acid sites in severe acute respiratory syndrome (SARS) coronavirus (CoV) are evolved by positive Darwinian selection. These lines of evidence suggest an interesting evolutionary pattern of the respiratory viruses. At the genomic level, whether a gene, or a particular amino acid within a gene, is under relaxed selection or remains functionally constrained throughout evolution can be detected by comparing the rate of nonsynonymous nucleotide substitutions per nonsynonymous site (d~N~) with that of synonymous substitutions per synonymous site (d~S~) ([@bib20]). If d~N~/d~S~ (hereafter referred as *ω*) is greater than one, then positive selection is said to be operating. Alternatively, if *ω*  \< 1, the gene is under strong purifying selection and presumed to be functionally constrained.

Identifying genes that have evolved by adaptation is central to understanding molecular evolution. However, not all amino acid differences observed among the closely related sequences from ecologically/geographically isolated strains are adaptive (e.g., [@bib53]). Therefore, analyzing patterns of amino acid substitutions would provide insight into understanding protein adaptation by identifying candidate codon sites on which positive selection has been operating. Identifying the positively selected amino acid sites would also help in further immunization studies. Maximum likelihood (ML)-based codon substitution models, which account for variable *ω* ratios among codon sites and detect codon sites that are subjected to positive selection ([@bib49]), have been widely used in detecting positive selection in a number of respiratory viral groups (e.g., [@bib53], [@bib51]). Here we used [@bib49] ML codon substitution models to test whether there was evidence at the nucleotide sequence level that a subset of amino acid sites in G-protein of hMPV sequences that represent each subgroup has been under positive selection. In addition, we used a Bayesian MCMC approach implemented in BEAST version 1.4.4 ([@bib8]) that utilize the number and temporal distribution of genetic differences among viruses sampled at different times ([@bib10], [@bib9]) to estimate the evolutionary change for each lineage.

A total of 144 published unique nucleotide coding sequences of G-protein representing four sub-lineages (1a = 46, 1b = 40, 2a = 38, 2b = 20) were retrieved from GenBank ([Table 1](#tbl1){ref-type="table"} ). Sequences were aligned using Mesquite version 1.2 ([@bib27]), DAMBE version 4.5.2 ([@bib46], [@bib47]), and BioEdit version 7.0.5.3 ([@bib18]) software packages. To infer phylogenetic relationship among these strains of hMPVs, we reconstructed a neighbor joining tree from their predicted amino acid sequence data with *p*-distance implemented in MEGA version 3.1 ([@bib23]). Using the same program, nodal supports were estimated with 10,000 nonparametric bootstrap replicates. For selection analyses, we reconstructed unrooted ML trees for each lineage from their respective nucleotide sequence data using the appropriate nucleotide substitution model identified by the hierarchical likelihood ratio test implemented in Modeltest version 3.5 ([@bib32]). PHYML version 2.4.4 ([@bib17]) was used to conduct ML analyses.Table 1GenBank accession number, strain name, country of origin, and the year of isolation of 144 unique hMPV G-protein sequences used in the studyGenBank No.Strain nameCountry of originYear of IsolationSourceGroup[AF371337](AF371337)00-1The Netherlands [@bib43]1a[AY296015](AY296015)FL/4/01The Netherlands2001[@bib43]1a[AY296016](AY296016)FL/3/01The Netherlands2001[@bib43]1a[AY296017](AY296017)FL/8/01The Netherlands2001[@bib43]1a[AY296018](AY296018)FL/10/01The Netherlands2001[@bib43]1a[AY296019](AY296019)NL/10/01The Netherlands2001[@bib43]1a[AY296020](AY296020)NL/2/02The Netherlands2002[@bib43]1a[AY327802](AY327802)201-7182AustraliaGenBank1a[AY327803](AY327803)201-4199Australia--GenBank1a[AY327804](AY327804)Q01-6410Australia--GenBank1a[AY327805](AY327805)Q01-7262Australia--GenBank1a[AY327806](AY327806)Q01-6346Australia--GenBank1a[AY327807](AY327807)Q01-7292Australia--GenBank1a[AY327808](AY327808)Q01-7252AAustralia--GenBank1a[AY327809](AY327809)Q01-7292Australia--GenBank1a[AY327810](AY327810)Q016297Australia--GenBank1a[AY485232](AY485232)hMPV13-2000Canada2000[@bib31]1a[AY485235](AY485235)hMP V193-2002Canada2002[@bib31]1a[AY485236](AY485236)hMPV22-2001Canada2001[@bib31]1a[AY485238](AY485238)hMPV23-2001Canada2001[@bib31]1a[AY485251](AY485251)hMPV81-1999Canada1999[@bib31]1a[AY485254](AY485254)hMPV86316-2002Canada2002[@bib31]1a[AY485255](AY485255)hMPV88448-2002Canada2002[@bib31]1a[AY485256](AY485256)hMPV88470-2002Canada2002[@bib31]1a[AY530092](AY530092)JPS03-180Japan2003[@bib21]1a[AY574225](AY574225)CAN34-02Canada2002[@bib21]1a[AY574226](AY574226)CAN40-02Canada2002[@bib21]1a[AY574228](AY574228)CAN97-02Canada2002[@bib21]1a[AY574231](AY574231)CAN187-02Canada2002[@bib21]1a[AY574237](AY574237)CAN216-02Canada2002[@bib21]1a[AY574243](AY574243)CAN464-02Canada2002[@bib21]1a[AY574244](AY574244)CAN532-02Canada2002[@bib21]1a[AY848881](AY848881)RSA/39/01South Africa2001[@bib25]1a[AY848882](AY848882)RSA/1/02South Africa2002[@bib25]1a[AY848885](AY848885)RSA/4/02South Africa2002[@bib25]1a[AY848887](AY848887)RSA/17/02South Africa2002[@bib25]1a[AY848889](AY848889)RSA/31/01South Africa2001[@bib25]1a[AY848890](AY848890)RSA/33/01South Africa2001[@bib25]1a[AY848893](AY848893)RSA/8/02South Africa2002[@bib25]1a[AY848896](AY848896)RSA/3/02South Africa2002[@bib25]1a[AY848897](AY848897)RSA/10/02South Africa2002[@bib25]1a[AY848901](AY848901)RSA/14/02South Africa2002[@bib25]1a[AY848903](AY848903)RSA/34/01South Africa2001[@bib25]1a[DQ312444](DQ312444)IA3-2002USA2002[@bib16], [@bib15]1a[DQ362949](DQ362949)Arg/1/03Argentina2003[@bib14]1a[DQ362950](DQ362950)Arg/2/02Argentina2002[@bib14]1a[AY296021](AY296021)NL/17/00The Netherlands2000[@bib44]1b[AY296022](AY296022)NL/1/81The Netherlands1981[@bib44]1b[AY296023](AY296023)NL/1/93The Netherlands1993[@bib44]1b[AY296025](AY296025)NL/3/93The Netherlands1993[@bib44]1b[AY296026](AY296026)NL/1/95The Netherlands1995[@bib44]1b[AY296028](AY296028)NL/13/96The Netherlands1996[@bib44]1b[AY296029](AY296029)NL/22/01The Netherlands2001[@bib44]1b[AY296030](AY296030)NL/24/01The Netherlands2001[@bib44]1b[AY296032](AY296032)NL/29/01The Netherlands2001[@bib44]1b[AY296033](AY296033)NL/302The Netherlands2002[@bib44]1b[AY485234](AY485234)hMPV17-2000Canada2000[@bib31]1b[AY485250](AY485250)hMPV80-1999Canada1999[@bib31]1b[AY530090](AY530090)JPS03-176Japan2003[@bib21]1b[AY530091](AY530091)JPS03-178Japan2003[@bib21]1b[AY530093](AY530093)JPS03-187Japan2003[@bib21]1b[AY530095](AY530095)JPS03-240Japan2003[@bib21]1b[AY574227](AY574227)CAN58-02Canada2002[@bib1]1b[AY574229](AY574229)CAN164-02Canada2002[@bib1]1b[AY574230](AY574230)CAN182-02Canada2002[@bib1]1b[AY574234](AY574234)CAN197-02Canada2002[@bib1]1b[AY574235](AY574235)CAN208-02Canada2002[@bib1]1b[AY574236](AY574236)CAN215-02Canada2002[@bib1]1b[AY574241](AY574241)CAN348-02Canada2002[@bib1]1b[AY848910](AY848910)RSA/27/00South Africa2000[@bib25]1b[AY848911](AY848911)RSA/7/00South Africa2000[@bib25]1b[AY848912](AY848912)RSA/26/00South Africa2000[@bib25]1b[AY848914](AY848914)RSA/7/01South Africa2000[@bib25]1b[AY848915](AY848915)RSA/20/00South Africa2000[@bib25]1b[AY848916](AY848916)RS A/20/01South Africa2001[@bib25]1b[AY848917](AY848917)RSA/49/00South Africa2000[@bib25]1b[AY848919](AY848919)RSA/44/00South Africa2000[@bib25]1b[DQ270215](DQ270215)BJ1819China2000GenBank1b[DQ312449](DQ312449)IA-8-2003USA2003[@bib16]1b[DQ270217](DQ270217)BJ1824China--GenBank1b[DQ312458](DQ312458)IA-17-2003USA2003[@bib16]1b[DQ312462](DQ312462)IA21-2004USA2004[@bib16]1b[DQ312463](DQ312463)IA22-2004USA2004[@bib16]1b[DQ312464](DQ312464)IA23-2004USA2004[@bib16]1b[DQ362952](DQ362952)Arg/3/00Argentina2000[@bib14]1b[NC_004148](NC_004148)CAN97-83Canada1997[@bib3]1b[AY296040](AY296040)NL/1/94The Netherlands1994[@bib44]2a[AY296041](AY296041)NL/1/82The Netherlands1982[@bib44]2a[AY296042](AY296042)NL/1/96The Netherlands1996[@bib44]2a[AY296044](AY296044)NL/9/00The Netherlands2000[@bib44]2a[AY296045](AY296045)NL/3/01The Netherlands2001[@bib44]2a[AY296046](AY296046)NL/4/01The Netherlands2001[@bib44]2a[AY296047](AY296047)UK/5/01UK2001[@bib44]2a[AY297748](AY297748)CAN98-75Canada1998[@bib3]2a[AY485243](AY485243)hMPV73-1998Canada1998[@bib31]2a[AY485244](AY485244)hMPV74-1998Canada1998[@bib31]2a[AY485245](AY485245)hMPV75-1998Canada1998[@bib31]2a[AY485246](AY485246)hMPV76-1998Canada1998[@bib31]2a[AY485247](AY485247)hMPV77-1998Canada1998[@bib31]2a[AY485248](AY485248)hMPV78-1998Canada1998[@bib31]2a[AY485249](AY485249)hMPV79-1998Canada1998[@bib31]2a[DQ270219](DQ270219)BJ1921China--GenBank2a[DQ270220](DQ270220)BJ2034China--GenBank2a[DQ270221](DQ270221)BJ4879China--GenBank2a[DQ270222](DQ270222)BJ4944China--GenBank2a[DQ270223](DQ270223)BJ5128China--GenBank2a[DQ270224](DQ270224)BJ5129China--GenBank2a[DQ312443](DQ312443)IA2-2002USA2002[@bib16]2a[DQ312457](DQ312457)IA16-2003USA2003[@bib16]2a[DQ312460](DQ312460)IA19-2003USA2003[@bib16]2a[DQ393715](DQ393715)Peru1-2002USA2002[@bib15]2a[DQ843658](DQ843658)BJ1816China--GenBank2a[AY848861](AY848861)RSA/4/00South Africa2000[@bib25]2a[AY848862](AY848862)RSA/71/00South Africa2000[@bib25]2a[AY848864](AY848864)RSA/37/00South Africa2000[@bib25]2a[AY848865](AY848865)RSA/16/00South Africa2000[@bib25]2a[AY848866](AY848866)RSA/12/00South Africa2000[@bib25]2a[AY848868](AY848868)RSA/29/00South Africa2000[@bib25]2a[AY848869](AY848869)RSA/58/00South Africa2000[@bib25]2a[AY848875](AY848875)RSA/54/00South Africa2000[@bib25]2a[AY848878](AY848878)RSA/23/00South Africa2000[@bib25]2a[AY848879](AY848879)RSA/90/00South Africa2000[@bib25]2a[AY848880](AY848880)RSA/93/00South Africa2000[@bib25]2a[DQ312453](DQ312453)IA12-2003USA2003[@bib16]2a[AY296034](AY296034)NL/1/99The Netherlands1999[@bib44]2b[AY296035](AY296035)NL/11/00The Netherlands2000[@bib44]2b[AY296036](AY296036)NL/12/00The Netherlands2000[@bib44]2b[AY296037](AY296037)NL/5/01The Netherlands2001[@bib44]2b[AY296038](AY296038)NL/9/01The Netherlands2001[@bib44]2b[AY296039](AY296039)NL/21/01The Netherlands2001[@bib44]2b[AY485242](AY485242)hMPV33-2001Canada2001[@bib31]2b[AY485252](AY485252)hMPV82-1997Canada1997[@bib31]2b[AY530089](AY530089)JPS02-76Japan2002[@bib21]2b[DQ312445](DQ312445)IA4-2002USA2002[@bib16]2b[DQ312446](DQ312446)IA5-2002USA2002[@bib16]2b[DQ312448](DQ312448)IA7-2003USA2003[@bib16]2b[DQ312454](DQ312454)IA13-2003USA2003[@bib16]2b[DQ312455](DQ312455)IA14-2003USA2003[@bib16]2b[DQ312461](DQ312461)IA20-2003USA2003[@bib16]2b[DQ393716](DQ393716)Peru2-2002Peru2002[@bib15]2b[DQ393717](DQ393717)Peru3-2003Peru2003[@bib15]2b[DQ393718](DQ393718)Peru4-2003Peru2003[@bib15]2b[DQ393719](DQ393719)Peru5-2003Peru2003[@bib15]2b[AY530094](AY530094)JPS03-194Japan 2003[@bib21] 2b

Overall substitution rate (nucleotide substitutions per site per year) of each lineage was estimated using the Bayesian skyline model, with both relaxed (variable) molecular clock (with uncorrelated lognormal model) and strict clock implemented in the BEAST version 1.4.4 ([@bib8]). This model employs a Bayesian MCMC approach and utilize the number and temporal distribution of genetic differences among viruses sampled at different times ([@bib10], [@bib9]). Bayesian skyline plots with 10 grouped intervals were reconstructed to infer demographic history ([@bib11]). Phylogenies were evaluated using a chain length of 30 million states under the HKY85 + Γ~4~ substitution model and with uncertainty in the data reflected in the 95% high-probability density (HPD) intervals. Convergence of trees was checked using Tracer version 1.3 ([@bib33]).

To determine the synonymous and nonsynonymous sequence divergence distribution pattern across the entire coding region of each lineage ([Fig. 1](#fig1){ref-type="fig"} ), we used a sliding window approach (window size = 6, step = 1) implemented in DNAsp version 4.0 ([@bib35]).Fig. 1NJ tree inferred from 144 amino acid sequences of human metapneumovirus G glycoprotein representing four lineages. Nodal support is mentioned at the base of the node. The sliding window analyses of respective lineages show the synonymous and nonsynonymous divergence.

To assess whether positive selection is operating in any codon sites, we used the alignment and ML trees of respective lineages as input for the CODEML program of PAML version 3.15 ([@bib48]). The PAML program incorporates six different codon substitution models that account for variable *ω* for each codon site. The six codon substitution models are: M0 (one-ratio), M1a (nearly neutral), M2a (positive selection), M7 (*β* distribution; 0 ≤  *ω*  ≤ 1), M8 (*β*  +  *ω*  \> 1: continuous) ([@bib49]), and M8a (*β*  +  *ω*  = 1) ([@bib38]). The M0 model estimates overall *ω* for the data. The M1a model estimates a single parameter, *p* ~0~, with *ω* ~0~  = 0, and the remaining sites with frequency *p* ~1~ (*p* ~1~  = 1 −  *p* ~0~) assuming *ω* ~1~  = 1. The M2a model adds a class of positively selected sites with frequency *p* ~2~ (where *p* ~2~  = 1 −  *p* ~1~  −  *p* ~0~) with *ω* ~2~ estimated from the data. In the M7 model, *ω* follows a beta distribution and is allowed to vary between 0 and 1, and two parameters (*p* and *q*) of the beta distribution are estimated from the data. In the M8 model, a proportion, *p* ~0~ *,* of sites have *ω* drawn from the beta distribution and the remaining sites with proportion *p* ~1~ are positively selected (*ω* ~1~  \> 1). The LRTs between nested models were conducted by comparing twice the difference in log-likelihood values (2lnΔ*l*) against a *χ* ^2^-distribution with degrees of freedom equal to the difference in the number of parameters between models ([@bib48]). Three LRTs were conducted. The first comparison was made between M1a, which allows for two site classes (0 \<  *ω*  \< 1, *ω*  = 1), and M2a, which allows three site classes (0 \<  *ω*  \< 1, *ω*  = 1 or *ω*  \> 1). The second comparison was between M7 and M8, and the last comparison was between M8 and M8a, in which *ω* for M8a was constrained to 1. In all LRTs good evidence for positive selection is found if the LRT indicates that models that allow for selection (i.e. M2a and M8; alternative models) are significantly better than their respective null models (M1a, M7 and M8a) ([@bib48]). Posterior probabilities of the inferred positively selected sites were estimated by the Bayes empirical Bayes (BEB) approach that takes sampling errors into account ([@bib50]).

Consistent with earlier studies ([@bib31]), G-protein based phylogeny in the present study has also revealed the existence of multiple lineages of this virus ([Fig. 1](#fig1){ref-type="fig"}). All four lineages showed some degree of spatial structure; however, few strains in each lineage did not show any spatial structure, indicating extensive viral gene flow across the regions in a given epidemic season. Relatively weak temporal structure across the regions further suggested that either certain strains can remain stable for more than one epidemic season (e.g., HRSV, [@bib53], [@bib52]), or mutations might not have occurred in a linear fashion with the preservation of changes in the circulating viral strains. Thus, virus genotypes would frequently appear and disappear along with new mutations in the populations. However, HRSV ([@bib53], [@bib52]) showed a strong correlation between the accumulation of genetic divergence and the isolation date of the sequences. Based on the relaxed clock assumption, the evolutionary rate of each major lineage of hMPVs (1 and 2; [Table 2](#tbl2){ref-type="table"} ) are 5.18 × 10^−3^ and 6.49 × 10^−3^  substitutions/site/year, respectively. Although these rates are compatible with the substitution rates reported for influenza viruses ([@bib6]), these rates are higher than the estimates of HRSV (HRSV A: 1.83 × 10^−3^, [@bib53]; HRSV B: 1.95 × 10^−3^, [@bib52]; HRSV-BA: 3 × 10^−3^  substitutions/site/year, [@bib39]; HRSV-A: 2.6 × 10^−3^, HRSV-B: 3.5 × 10^−3^, [@bib29]) and other paramyxoviruses (e.g., measles: [@bib45]). These discrepancies in the evolutionary rates could be associated with the differential selective pressures targeting different genomic regions. For example, the presence of a greater number of adaptively evolved amino acid sites in the gene can cause an accelerated rate of evolution. As a consequence, the overall evolutionary rate is expected to be higher ([@bib39]). Both major lineages of hMPVs showed interesting population dynamics ([Fig. 2](#fig2){ref-type="fig"} ). The times to the most recent common ancestor for lineage 1 and 2 are 49.452 (29.08--70.8) and 26.091 (21--36.651) years, respectively. While the population size of lineage 1 recently declined, the lineage 2 population size did not show any declining trend. This contrast in the population size could be associated with fitness of the virus.Table 2Mean nucleotide substitution rates (95% HPD interval in parenthesis) in hMPV G-gene estimated using Bayesian MCMC approach, with both relaxed and strict clockLineageRelaxed clockStrict clockSubstitution rate (×10^−3^ substitutions/site/year)Likelihood scoreSubstitution rate (×10^−3^ substitutions/site/year)Likelihood score1a4.58 (2.400--7.048)−2250.4814.152 (2.235--6.196)−2256.1561b5.344 (3.995--6.898)−2946.8244.817 (3.809--5.889)−2975.0212a6.139 (4.318--7.825)−2530.2805.275 (3.733--6.798)−2556.5082b7.865 (4.060--11.63)−1840.0663.795 (2.687--7.625)−1868.5071(a + b)5.182 (3.761--6.781)−4689.1614.621 (3.639--5.647)−4702.7172(a + b)6.494 (4.599--8.438)−3783.3204.770 (3.555--6.012)−3833.563[^1]Fig. 2Skyline plots estimated from Bayesian MCMC analyses of hMPV G-protein sequences belong to lineage 1(a + b) and lineage 2(a + b). Population size (in *Y*-axis) is expressed in logarithmic scale. The solid line shows the median estimate of population size (Ne × g) throughout the given time period. The grey area gives the 95% HPD interval of these estimates.

Despite the weak temporal and spatial structure, viral strains belonging to lineage 1a (Australia, Canada, The Netherlands, South Africa, USA, Argentina, and Japan) and 1b (Canada, The Netherlands, South Africa, USA, Japan, China, and Argentina) have a wider geographic spread than the strains belonging to lineage 2a (Canada, UK, The Netherlands, USA, China, and South Africa) and 2b (The Netherlands, Canada, USA, Peru, and Japan), indicating that fitness of the viral strains might have played a crucial role in the uneven distribution across the wide geographic regions. The extensive polymorphisms of the hMPV G-gene may have resulted from mutations occurring during virus propagation in cell culture; however, [@bib31] reported identical sequences of the same viral strain after multiple passages, and thus, the observed variation in the G-gene of hMPVs due to multiple passages is more unlikely. However, it is unclear whether the hMPV G-gene experienced differential selection pressures, or all the deduced amino acid sites evolved due to stochastic mutational processes? Sliding window analyses of each lineage revealed that in the majority of regions synonymous divergence exceeds the corresponding nonsynonymous divergence, thus suggesting that the G-gene of hMPV is influenced by purifying selection ([Fig. 1](#fig1){ref-type="fig"}). However, a few coding regions in all the lineages showed relatively higher nonsynonymous divergence than synonymous divergence, therefore indicating the pervasive role of positive selection in certain amino acid sites. To identify the codon sites that are positively selected, we performed ML-based codon substitution analyses. Consistent with sliding window results, the M0 model revealed that the average *ω* for each lineage is less than one ([Table 3](#tbl3){ref-type="table"} ), thus suggesting each lineage experienced purifying selection. However, comparison of the models that assume positive selection (M2a, M8) with the models (M1a, M7, and M8a) that assume no positive selection, detected approximately 6%, 1.3%, 7.3%, and 3% positively selected codons in lineage 1a, 1b, 2a, and 2b, respectively ([Table 3](#tbl3){ref-type="table"}). There are eight positively selected sites (site 93, 105, 106, 154, 158, 171, 173, and 188) with posterior probability ≥0.95 within lineage 1a, whereas lineage 1b (site 146, 183, and 196) and lineage 2a (85, 232, and 239) each have three positively selected sites with posterior probability ≥0.95. Lineage 2b has only two positively selected sites (site 100 and 105) with posterior probability ≥0.95. Except site 105, which is positively selected in lineage 1a and 2b, none of the positively selected sites are overlapping among the lineages. It is unclear whether these positively selected sites are associated with the fitness of this virus. Research with monoclonal antibodies has shown that the hMPV F-protein carries neutralizing epitopes ([@bib36], [@bib40]); therefore, antigenic variation due to immune selection in the hMPV F-protein is more likely. Although, the overall excess of synonymous substitutions at the hMPV G-protein indicates that host immune selection might not be the dominant selective force, the findings of several hotspots of nonsynonymous substitutions in this protein suggests that host immune selection might also play a role in maintaining diversity. Recent study has shown that a majority of the neutralizing epitopes in the HRSV G-gene is strongly associated with positively selected sites, and some of the positively selected sites correspond to the sites of *O*-glycosylation ([@bib53]). Like HRSV, although all the positively selected codons of hMPV G-gene are located in the extracellular domain and some of them correspond to sites of *O*-glycosylation, the putative role is still unclear for these positively selected sites, as is whether some of these positively selected sites are associated with the region of antigenic determinants. We intended to map these positively selected sites with the HRSV G-protein to see whether the same sites were also positively selected in HRSV ([@bib53], [@bib52]); however, the predicted G-gene amino acid sequences of the two viruses could not be aligned ([@bib42], [@bib22]). Although a vast majority of codon sites (\>95% in most cases) are shown to have been under purifying selection, significantly higher *ω* values (\>1) at certain codon sites ([Table 3](#tbl3){ref-type="table"}) indicate the hMPV G-gene is under positive selection. Identification of these positively selected amino acid sites would help in better screening using epitope mapping technology to identify and localize the sites that can be recognized by the immune system. Knowledge of sites that have adaptively evolved can greatly cut the cost of these screening processes and thereby help in developing better immunization techniques ([@bib30]).Table 3Test for variable selection pressures on different codons based on ML-based codon substitution models of [@bib49]ModelFree parametersParameter estimatesLikelihood scoresModel comparison (2Δ*l*, d.f., *p*)Positively selected sites*ω* ± S.E.**Lineage 1a** M0: One-ratio1*ω* = **0.6152**−2510.069374None M1a: Nearly neutral1*ω*~0~ = 0.1, *ω*~1~ = 1, (*p*~0~ = 0.62, *p*~1~ = 0.38)−2473.399503Not allowed   M2a: Positive selection3*ω*~0~ = 0, *ω*~1~ = 1, ***ω***~**2**~ = **7.31**; (*p*~0~ = 0.62, *p*~1~ = 0.32, ***p***~**2**~ = **0.06**)−2444.710131(M1a vs. M2a), 57.378744, d.f. = 2, *p* = 0.000093-H(0.989)7.523 ± 1.614105-Y (0.987)7.504 ± 1.640106-F (1.000)7.595 ± 1.464143-K (0.748)5.832 ± 3.077154-P (1.000)7.594 ± 1.466155-R(0.667)5.263 ± 3.239158-S (0.980)7.456 ± 1.718171-R(0.958)7.323 ± 1.953173-T (0.971)7.380 ± 1.805176-T (0.583)4.674 ± 3.305188-T (0.973)7.393 ± 1.788   M7: *β*2*p* = 0.1085, *q* = 0.1183−2474.985643Not allowed   M8: *β* + ω~s~ \> 14*p*~0~ = 0.94, ***p***~**1**~ = **0.06**, *p* = 0.36716, *q* = 0.47347, ***ω*** = **6.83**−2444.453952(M7 vs. M8), 61.063382, d.f. = 2, *p* = 0.000093-H (0.993)7.265 ± 1.428105Y (0.993)7.264 ± 1.426106-F (1.000)7.307 ± 1.332143-K (0.814)6.055 ± 2.779154-P (1.000)7.306 ± 1.332155-R (0.744)5.575 ± 3.020156-T (0.649)4.762 ± 2.999158-S (0.990)7.242 ± 1.468171-R(0.970)7.119 ± 1.718173-T (0.989)7.228 ± 1.480176-T (0.664)5.028 ± 3.191188-T (0.991)7.239 ± 1.460   M8a: *β* + *ω*~s~ = 13*p*~0~ = 0.62, *p*~1~ = 0.38, *p* = 11.37, *q* = 99, *ω* = 1−2473.400411(M8 vs. M8a), 57.892918, d.f. = 1, *p* = 0.0000Not allowed  **Lineage 1b** M0: One-ratio1***ω*** = **0.4649**−3088.137934None M1a: Nearly neutral1*ω*~0~ = 0.166, *ω*~1~ = 1, (*p*~0~ = 0.72, *p*~1~ = 0.28)−3048.588195Not allowed   M2a: Positive selection3*ω*~0~ = 0.179, *ω*~1~ = 1, ***ω***~2~ = **9.729**; (*p*~0~ = 0.696, *p*~1~ = 0.289, ***p***~**2**~ = **0.013**)−3028.791341(M1a vs. M2a), 39.593708, d.f. = 2, *p* = 0.0000146-P (1.00)8.326 ± 1.713183-F (1.00)8.325 ± 1.714196-L (0.999)8.316 ± 1.732   M7: *β*2*p* = 0.393, *q* = 0.546−3054.125576Not allowed   M8: *β* + *ω*~s~ \> 14*p*~0~ = 0.89, ***p***~**1**~ = **0.11***p* = 1.777, *q* = 4.03, ***ω*** = **2.84**−3034.377594(M7 vs. M8), 39.495964, d.f. = 2, *p* = 0.0000146-P (1.000)5.183 ± 1.880157-F (0.718)3.601 ± 2.137183-F (1.000)5.183 ± 1.880196-L (0.999)5.181 ± 1.882199-S (0.573)2.935 ± 2.110   M8a: *β* + ω~s~ = 13*p*~0~ = 0.72, *p*~1~ = 0.28, *p* = 19.98, *q* = 99, ω = 1−3048.6126(M8 vs. M8a), 28.470012, d.f. = 1, *p* = 0.0000Not allowed  **Lineage 2a** M0: One-ratio1***ω*** = **0.6898**−2927.296491None M1a: Nearly neutral1*ω*~0~ = 0.248, *ω*~1~ = 1, (*p*~0~ = 0.565, *p*~1~ = 0.435)−2913.654666Not allowed   M2a: Positive selection3*ω*~0~ = 0.382, ***ω***~2~ = **4.487**; (*p*~0~ = 0.69, *p*~1~ = 0.23, ***p***~**2**~ = **0.073**)−2898.698295(Mla vs. M2a), 29.912742, d.f. = 2, *p* = 0.000085-L (1.000)5.340 ± 1.57093-Q (0.888)4.839 ± 2.038105-L (0.878)4.694 ± 1.966109-S(0.913)4.898 ± 1.899113-L (0.732)3.959 ± 2.193121-P (0.510)2.849 ± 2.078180-L (0.535)3.024 ± 2.228202-S (0.508)2.890 ± 2.196232-Y (0.989)5.295 ± 1.627239-P (0.975)5.226 ± 1.690   M7: *β*2*p* = 0.606, *q* = 0.379−2917.092133Not allowed   M8: *β* + *ω*~s~ \> 14*p*~0~ = 0.89, ***p***~**1**~ = **0.11**, *p* = 28.418, *q* = 31.77, ***ω*** = **3.65**−2898.947133(M7 vs. M8), 36.29, d.f. = 2, *p* = 0.000085-L (1.000)5.381 ± 1.32493-Q (0.900)4.945 ± 1.872105-L (0.920)4.988 ± 1.751109-S (0.939)5.093 ± 1.673113-L (0.777)4.282 ± 2.179121-P (0.528)3.028 ± 2.275180-L (0.546)3.173 ± 2.375202-S (0.519)3.038 ± 2.358232-Y (0.992)5.351 ± 1.376239-P (0.983)5.306 ± 1.439   M8a: *β* + *ω*~s~ = 13*p*~0~ = 0.57, *p*~1~ = 0.43, *p* = 33.25, *q* = 99, *ω* = 1−2913.719868(M8 vs. M8a), 29.54547 d.f. = 1, *p* = 0.0000Not allowed  **Lineage 2b** M0: One-ratio1***ω*** = **0.7065**−1855.459267None M1a: Nearly neutral1ω~0~ = 0, ω~1~ = 1, (*p*~0~ = 0.49, *p*~1~ = 0.51)840.547215Not allowed   M2a: Positive selection3*ω*~0~ = 0, *ω*~1~ = 1, ***ω***~**2**~ = **10.0195**; (*p*~0~ = 0.45, *p*~1~ = 0.52, ***p***~**2**~ = **0.03**)−1829.903873(M1a vs. M2a), 21.286684, d.f. = 2, *p* = 0.00002100-E (0.999)7.607 ± 2.041105-P (0.971)7.432 ± 2.288109-P (0.911)6.994 ± 2.703213-R (0.682)5.477 ± 3.516   M7: *β*2*p* = 0.00517, *q* = 0.005−1840.570751Not allowed   M8: *β* + *ω*~s~ \> 14*p*~0~ = 0.97, ***p***~**1**~ = **0.03**, *p* = 0.005, *q* = 0.005, ***ω*** = **9.6**830.002479(M7 vs. M8), 21.136554, d.f. = 2, *p* = 0.00003100-E (1.000)6.823 ± 2.093105-P (0.985)6.745 ± 2.196109-P (0.958)6.561 ± 2.375114-Y (0.515)3.679 ± 3.226116-G (0.572)4.071 ± 3.293162-E (0.606)4.080 ± 3.052201-T (0.500)3.579 ± 3.206213-R (0.770)5.424 ± 3.159220-P (0.629)4.385 ± 3.236   M8a: *β* + *ω*~s~ = 13*p*~0~ = 0.49, *p*~1~ = 0.51, *p* = 0.005, *q* = 2.785, *ω* = 1840.547213(M8 vs. M8a), 21.089468, d.f. = 1, *p* = 0.0000Not allowed[^2]
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[^1]: Estimates with relaxed clock are better fit to the data.

[^2]: Null models (M1a, M7, and M8a) are compared with their respective alternative models (M2a, M8) that allow *ω* \> 1. Proportion of positively selected sites and their corresponding *ω*-values in M2a and M8 models are in bold. The posterior probability of each positively selected amino acid site is in parenthesis. Posterior probabilities are estimated based on Bayes Empirical bayes analyses ([@bib50]).
